{"id":10354,"date":"2022-09-27T04:47:04","date_gmt":"2022-09-27T04:47:04","guid":{"rendered":"https:\/\/marylanddailygazette.com\/glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\/"},"modified":"2022-09-27T04:47:04","modified_gmt":"2022-09-27T04:47:04","slug":"glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\/","title":{"rendered":"Glaucoma Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\">Glaucoma Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight<\/a><\/p>\n<p><div><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/aPs0SZ.png\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Glaucoma Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/aPs0SZ.png\" alt=\"Glaucoma Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" width=\"225\"><\/a><\/div>\n<p><strong><em>\u201cDelveInsight\u2019s Glaucoma Pipeline Insight, 2022,\u201d report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Glaucoma pipeline landscape\u201d<\/em><\/strong><\/p>\n<p>It covers the <a href=\"https:\/\/www.delveinsight.com\/report-store\/glaucoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Glaucoma Pipeline<\/a> drug profiles, including clinical and nonclinical stage products. It also covers the Glaucomatherapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p><strong>Key takeaways from the GlaucomaPipeline Report<\/strong><\/p>\n<ul>\n<li>DelveInsight\u2019s <strong>Glaucoma<\/strong> Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.<\/li>\n<li>The <strong>Glaucoma<\/strong> pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.<\/li>\n<li>Glaucoma Pipeline Companies include <strong><em>Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,&nbsp; HK inno.N, Avirmax Inc<\/em><\/strong>., and many others.<\/li>\n<li>Glaucoma Pipeline Therapies include <strong><em>QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP \u2013 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 \/ BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010,<\/em><\/strong> and many others.<\/li>\n<\/ul>\n<p><strong>To know more about the GlaucomaPipeline report, click here:-<a href=\"https:\/\/www.delveinsight.com\/report-store\/glaucoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/glaucoma-pipeline-insight<\/a><\/strong><\/p>\n<p><strong>Glaucoma Overview<\/strong><\/p>\n<p>A glaucoma is a group of eye diseases causing optic nerve damage. The optic nerve carries images from the retina, which is the specialized light sensing tissue, to the brain so we can see. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve. When a significant number of nerve fibers are damaged, blind spots develop in the field of vision. Once nerve damage and visual loss occur, it is permanent. Most people don\u2019t notice these blind areas until much of the optic nerve damage has already occurred. If the entire nerve is destroyed, blindness results. Glaucoma is a leading cause of blindness in the world, especially in older people.<\/p>\n<p>Early detection and treatment by your ophthalmologist are the keys to preventing optic nerve damage and vision loss from glaucoma. The exact causes of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and\/or decreased blood flow of the optic nerve. Although high eye pressure sometimes leads to glaucoma, many people can also develop glaucoma with \u201c\u201dnormal\u201d\u201d eye pressure. The treatment for glaucoma depends upon the nature and severity of each case. In general, glaucoma cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. With any type of glaucoma, regular eye examinations are very important to detect progression and to prevent vision loss.<\/p>\n<p><strong>Glaucoma Pipeline Insight Report<\/strong><\/p>\n<p>\u201cGlaucoma \u2013 Pipeline Insight, 2022\u201d report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glaucoma pipeline landscape is provided which includes the disease overview and Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p><strong>DelveInsight\u2019s Glaucoma Pipeline report covers around&nbsp;70+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul>\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/glaucoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Glaucoma Emerging Drugs <\/strong><\/a><strong>under Different Phases of Clinical Development Include:-<\/strong><\/p>\n<ul>\n<li>QLS-101: Qlaris Bio, Inc.<\/li>\n<li>NCX 470: Nicox<\/li>\n<\/ul>\n<p><strong>Glaucoma Pipeline Therapeutics Analysis<\/strong><\/p>\n<p>There are approx. 70+ key companies which are developing therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Nicox.<\/p>\n<p><strong>Glaucoma Pipeline&nbsp;development activities<\/strong><\/p>\n<p>The <strong>Glaucoma <\/strong>pipeline report provides insights into:<\/p>\n<ul>\n<li>All of the companies that are developing therapies for the treatment of&nbsp;<strong>Glaucoma<\/strong> with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;<strong>Glaucoma<\/strong><\/li>\n<li><strong>Glaucoma <\/strong>key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;M<strong> Glaucoma<\/strong><\/li>\n<\/ul>\n<p>The&nbsp;<strong>Glaucoma <\/strong>Pipeline Report is built using data and information traced from the researcher\u2019s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p><strong>Request for Sample PDF Report to know more about glaucoma&nbsp;Drugs and therapies \u2013<a href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/glaucoma-pipeline-insight<\/a><\/strong><\/p>\n<p><strong>Scope of the Glaucoma Pipeline Report<\/strong><\/p>\n<ul>\n<li><strong>Coverage<\/strong>:&nbsp;Global<\/li>\n<li><strong>Therapeutic Assessment By Product Type:&nbsp;<\/strong>Mono, Combination, Mono\/Combination<\/li>\n<li><strong>Therapeutic Assessment By Clinical Stages:&nbsp;<\/strong>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Route of Administration:<\/strong>&nbsp;Inhalation, Parenteral, Intranasal, Intravenous, Oral, Subcutaneous<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Molecule Type<\/strong>: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Mechanism of Action:&nbsp;<\/strong>KATP channel modulators, Nitric oxide donors, Protein kinase inhibitors, Carbonic anhydrase inhibitors, Prostaglandin F2 alpha agonists, Antioxidants, Electron transport chain complex protein modulators, TIE-2 receptor modulators, Cannabinoid receptor agonists<\/li>\n<li><strong>Key Glaucoma Companies<\/strong>: Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,&nbsp; HK inno.N, Avirmax Inc., and others.<\/li>\n<li><strong>Key Glaucoma Pipeline Therapies<\/strong>: QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP \u2013 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 \/ BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010,&nbsp; and others.<\/li>\n<\/ul>\n<p><strong>Table of Content<\/strong><\/p>\n<ol start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Glaucoma: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Glaucoma \u2013 DelveInsight\u2019s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>NCX 470: Nicox<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>QLS-101: Qlaris Bio, Inc.<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>ONL 1204: ONL Therapeutics<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>RTC 1119: Ripple Therapeutics<\/li>\n<li>Inactive Products<\/li>\n<li>Glaucoma Key Companies<\/li>\n<li>Glaucoma Key Products<\/li>\n<li>Glaucoma- Unmet Needs<\/li>\n<li>Glaucoma- Market Drivers and Barriers<\/li>\n<li>Glaucoma- Future Perspectives and Conclusion<\/li>\n<li>Glaucoma Analyst Views<\/li>\n<li>Glaucoma Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p><strong>Download Sample PDF Report for Glaucoma clinical trials advancements @&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/glaucoma-pipeline-insight<\/a><\/strong><\/p>\n<p> <strong>About Us<\/strong><\/p>\n<p>DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=glaucoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Mon, 26 Sep 2022 21:20:07 -0500<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glaucoma Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight \u201cDelveInsight\u2019s Glaucoma Pipeline Insight, 2022,\u201d report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Glaucoma pipeline landscape\u201d It covers the Glaucoma Pipeline drug profiles, including clinical and nonclinical stage [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10353,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10354"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=10354"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10354\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/10353"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=10354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=10354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=10354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}